ReviewCancer cell2017
The Microenvironmental Landscape of Brain Tumors.
Review in Cancer cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03189420 (Glioma Microenvironment an Exploratory Study), which is not on this map. Cited by 1,174 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Glioma Microenvironment an Exploratory Study
Who cites it
1,174 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clinical Trials with a Focus on Diffuse Midline Glioma.Targeted oncology · 2026Pooled it
- T cell immunity in glioma and potential implications for immunotherapy: A systematic review.Neuro-oncology · 2026Pooled it
- Structural optimization of CHI3L1 inhibitors with improved pharmacokinetics and functional activity in 3D glioblastoma models.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- The Microbiome in Glioblastoma: Mechanisms, Tumor-Immune Interactions, and Translational Perspectives.MicrobiologyOpen · 2026Review
- Mimicking tumor hypoxia in a glioblastoma-on-a-chip.Materials today. Bio · 2026Article
- Genetic orchestration of the primary central nervous system lymphoma microenvironment.Biomarker research · 2026Review
- Immune-related hallmark pathway heterogeneity identifies a prognostic risk signature with independent external validation in glioblastoma.Discover oncology · 2026Article
- Research Advances on Organelle-Targeted Drug Delivery Systems for the Treatment of Brain Tumors and Central Nervous System Inflammation.Pharmaceutics · 2026Review
- Redox Regulation in Glioblastoma: Mechanisms, Biomarkers, and Therapeutic Implications.International journal of molecular sciences · 2026Review
- Review
- Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Efficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAFJCO precision oncology · 2026Article
- Integrated Genomic and Tumor Microenvironment Subtyping Improved Risk Stratification in Primary Central Nervous System Lymphoma.American journal of hematology · 2026Article
- FAPExperimental & molecular medicine · 2026Article
- Spatial Omics in High-Grade Gliomas: Mapping Immune-Tumor Niches for Precision Therapy.Cancer medicine · 2026Review
- Contributions of previous whole-brain radiation therapy, cumulative intracranial tumor volume, and repeat radiosurgery to adverse radiation effects following stereotactic radiosurgery for brain metastasis.Clinical & experimental metastasis · 2026Article
- Ferroptosis as an immunometabolic checkpoint in brain tumours: spatial vulnerabilities and therapeutic opportunities.Molecular brain · 2026Review
- Increased glioblastoma risk in patients with myeloproliferative neoplasms and myelodysplastic syndromes.Clinical and experimental medicine · 2026Article
- NTAN1 Promotes Glioblastoma Malignant Progression and Is a Novel Prognostic Factor of Poor Prognosis.Biomedicines · 2026Article
- Immune niches in brain tumors: glial-immune cell interactions and spatial microdomains.Acta neuropathologica communications · 2026Review
1,114 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The brain tumor microenvironment (TME) is emerging as a critical regulator of cancer progression in primary and metastatic brain malignancies. The unique properties of this organ require a specific framework for designing TME-targeted interventions. Here, we discuss a number of these distinct features, including brain-resident cell types, the blood-brain barrier, and various aspects of the immune-suppressive environment. We also highlight recent advances in therapeutically targeting the brain TME in cancer. By developing a comprehensive understanding of the complex and interconnected microenvironmental landscape of brain malignancies we will greatly expand the range of therapeutic strategies available to target these deadly diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.